ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

MRK Merck and Co Inc

129,44
-1,65 (-1,26%)
25 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Merck and Co Inc MRK NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-1,65 -1,26% 129,44 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
131,74 129,16 131,74 129,49 131,09
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
20/5/202412:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/5/202422:15EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
15/5/202417:31EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
15/5/202412:45BWMerck to Present New Data at 2024 ASCO Annual Meeting..
13/5/202412:45BWMerck Provides Update on Phase 3 KeyVibe-010 Trial..
09/5/202413:05PRNCASanté Canada approuve KEYTRUDA® pour le traitement, en..
09/5/202412:45BWMerck Provides Update on Phase 3 KEYNOTE-B21 Trial..
08/5/202412:45BWMerck to Participate in the Bank of America Securities 2024..
06/5/202422:29EDGAR2Form 144 - Report of proposed sale of securities
06/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/5/202413:15BWMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary..
29/4/202415:00BWMerck Announces Positive Data for V116, an Investigational,..
25/4/202422:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
25/4/202415:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
25/4/202413:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202412:30BWMerck Announces First-Quarter 2024 Financial Results
19/4/202413:04PRNCASanté Canada approuve KEYTRUDA® comme traitement de première..
10/4/202413:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202412:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202414:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202412:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202411:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202411:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202423:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202411:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/3/202414:00BWMerck Announces Positive Data on V116, an Investigational,..
15/3/202421:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202411:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202408:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202413:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/3/202416:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/3/202415:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202412:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202412:45BWMerck to Participate in the Leerink Partners Global..
27/2/202412:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202412:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/2/202422:14EDGAR2Form 8-K - Current report
20/2/202412:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202413:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..

Dernières Valeurs Consultées

Delayed Upgrade Clock